Gujarat Inject (Kerala) share price
BSE: 524238Pharmaceuticals & BiotechnologySmall Cap
Last close ₹9.85up ₹0.06 (0.61%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹9.79.
52-week range of traded prices to 23 Oct 2026
₹2.04Low, 23 Oct 2025₹14.30High, 9 Jul 2026
- The board meets on 26 Oct 2026 to consider: issue of warrants and preferential issue of shares.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- Differs from the exchange's2,790th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Differs from the exchange's
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Differs from the exchange's
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- –
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 32.9%
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,31,147
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 16 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹12 Crdown 59.43%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1.25 Crdown 23.45%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 10.0%
Revenue by year
Peak revenue ₹36 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 3 of the 9 years shown
| ₹ crore | Sep 2024Filed 12 Nov | Dec 2024Filed 23 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 14 Aug | Sep 2025Filed 19 Nov | Dec 2025Filed 14 Feb | Mar 2026Filed 20 May | Jun 2026Filed 16 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.6 | 3.2 | 4.2 | 2.4 | 1.6 | 1.6 | 30.7 | 12.5 |
| Net profit | 0.6 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 1.6 | 1.3 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 7.1% | 6.7% | 1.7% | 3.0% | 4.3% | 2.3% | 5.3% | 10.0% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Trading, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +200.8% | +78.2% | +68.8% | 0.0% |
| 3 years | +115.3% | +145.3% | −12.2% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 and 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Gujarat Inject (Kerala) in market cap. 4 companies in the table last traded before then: their rows are priced on their last trade.
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Dipna PharmachemDPL | 10 | – | – | – | – | – | – | 0.00% |
 Adline Chem LabADLINE | 9 | – | – | – | – | – | −685.2% | 0.00% |
 Brawn BiotechBRAWN | 8 | 8.9 | 1.8 | – | +13.6% | 22.3% | −12.6% | 0.00% |
 Vivanza BiosciencesVIVANZA | 6 | 14.1 | 1.5 | 32.8 | +735.0% | 10.9% | 3.3% | 0.00% |
 Decipher LabsDECIPHER | 5 | – | 0.6 | – | −25.2% | – | −31.5% | 0.00% |
 Advik LaboratoriesADVIKLA | 4 | – | 58.0 | – | – | −180.6% | −14.5% | 0.00% |
 Shyama Computronics and ServicesSHYAMACOMP | 4 | – | 0.4 | 58.5 | +9.4% | – | 0.6% | 0.00% |
 Bharat Immunologicals & BiologicalsBIBCL | – | – | – | – | – | – | – | – |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
22 Oct · Board meeting
Meeting on 26 Oct 2026: issue of warrants and preferential issue of shares15 Oct · Business
15 Oct · Business
5 Oct · Business
Gujarat Inject (Kerala) share price by year
Each calendar year to 2025.Gujarat Inject (Kerala) share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 3.58 | +40.8% | 3.58 | 1.85 |
| 2024 | 2.54 | +77.2% | 2.57 | 0.87 |
| 2023 | 1.43 | +7.1% | 1.43 | 0.65 |
| 2022 | 1.34 | +763.2% | 1.34 | 0.24 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2022 is from its first session, 30 May 2022. The change in 2022 is on the close at the end of 2009, the last year before it with a trade.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 9.80 | 9.90 | 9.78 | 9.85 | 9.87 | 2,31,147 |
| 22 Oct 2026 | 9.05 | 9.79 | 9.01 | 9.79 | 9.61 | 4,29,108 |
| 21 Oct 2026 | 9.26 | 9.50 | 9.15 | 9.33 | 9.31 | 5,07,471 |
| 19 Oct 2026 | 10.00 | 10.00 | 9.37 | 9.60 | 9.70 | 2,94,362 |
| 16 Oct 2026 | 9.74 | 9.89 | 9.64 | 9.81 | 9.80 | 2,19,344 |
| 15 Oct 2026 | 9.55 | 9.65 | 9.50 | 9.59 | 9.58 | 2,46,445 |
| 14 Oct 2026 | 9.25 | 9.53 | 9.00 | 9.52 | 9.42 | 95,015 |
| 13 Oct 2026 | 9.59 | 9.59 | 8.90 | 9.08 | 9.36 | 2,08,317 |
| 12 Oct 2026 | 9.62 | 9.62 | 9.05 | 9.28 | 9.39 | 61,276 |
| 9 Oct 2026 | 9.59 | 9.59 | 9.05 | 9.40 | 9.36 | 3,88,710 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 8 Jul 2026 | Split | 0.1000 | Each share became 10. |
| 30 May 2022 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- Legal name
- Gujarat Inject (Kerala) Ltd.
- BSE code
- 524238
- ISIN
- INE659F01022
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 1992
- Face value
- ₹1
- CIN
- L46309GJ1991PLC151872
- Corporate identity number, the registrar of companies' code for it